Abstract
Alzheimer’s disease (AD) is a complex neurodegenerative disorder with a multi-faceted pathogenesis. So far, the therapeutic paradigm “one-compound-one-target” has failed and despite enormous efforts to elucidate the pathophysiology of AD, the disease is still incurable.
The multiple factors involved in AD include amyloid aggregation to form insoluble neurotoxic plaques of Aβ, hyperphosphorylation of tau protein, oxidative stress, calcium imbalance, mitochondrial dysfunction and deterioration of synaptic transmission. These factors together, accentuate changes in the CNS homeostasis, starting a complex process of interconnected physiological damage, leading to cognitive and memory impairment and neuronal death.
A recent approach for the rational design of new drug candidates, also called multitarget-directed ligand (MTDL) approach, has gained increasing attention by many research groups, which have developed a variety of hybrid compounds acting simultaneously on diverse biological targets. This review aims to show some recent advances and examples of the exploitation of MTDL approach in the rational design of novel drug candidate prototypes for the treatment of AD.
Keywords: Alzheimer’s disease, multi-target directed drugs, neurodegenerative disorders, rational drug design.
Current Neuropharmacology
Title:Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease
Volume: 12 Issue: 3
Author(s): Kris Simone Tranches Dias and Claudio Viegas
Affiliation:
Keywords: Alzheimer’s disease, multi-target directed drugs, neurodegenerative disorders, rational drug design.
Abstract: Alzheimer’s disease (AD) is a complex neurodegenerative disorder with a multi-faceted pathogenesis. So far, the therapeutic paradigm “one-compound-one-target” has failed and despite enormous efforts to elucidate the pathophysiology of AD, the disease is still incurable.
The multiple factors involved in AD include amyloid aggregation to form insoluble neurotoxic plaques of Aβ, hyperphosphorylation of tau protein, oxidative stress, calcium imbalance, mitochondrial dysfunction and deterioration of synaptic transmission. These factors together, accentuate changes in the CNS homeostasis, starting a complex process of interconnected physiological damage, leading to cognitive and memory impairment and neuronal death.
A recent approach for the rational design of new drug candidates, also called multitarget-directed ligand (MTDL) approach, has gained increasing attention by many research groups, which have developed a variety of hybrid compounds acting simultaneously on diverse biological targets. This review aims to show some recent advances and examples of the exploitation of MTDL approach in the rational design of novel drug candidate prototypes for the treatment of AD.
Export Options
About this article
Cite this article as:
Simone Tranches Dias Kris and Viegas Claudio, Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimer’s Disease, Current Neuropharmacology 2014; 12 (3) . https://dx.doi.org/10.2174/1570159X1203140511153200
DOI https://dx.doi.org/10.2174/1570159X1203140511153200 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurodegeneration and the Heat Shock Protein 70 Machinery: Implications for Therapeutic Development
Current Topics in Medicinal Chemistry Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment
CNS & Neurological Disorders - Drug Targets Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Ligands Targeting the Excitatory Amino Acid Transporters (EAATs)
Current Topics in Medicinal Chemistry Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Withania somnifera Phytochemicals Confer Neuroprotection by Inhibition of the Catalytic Domain of Human Matrix Metalloproteinase-9
Letters in Drug Design & Discovery Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration
Current Medicinal Chemistry Structurally Related Edaravone Analogues: Synthesis, Antiradical, Antioxidant, and Copper-Chelating Properties
CNS & Neurological Disorders - Drug Targets Using Mass Spectrometry-Based Peptidomics to understand the Brain and Disorders such as Parkinson’s Disease and Schizophrenia
Current Topics in Medicinal Chemistry Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Frontier View on Nanotechnological Strategies for Neuro-therapy
Current Drug Metabolism Amyotrophic Lateral Sclerosis Treatment with Ultramicronized Palmitoylethanolamide: A Case Report
CNS & Neurological Disorders - Drug Targets Inhibitors and Breakers of Advanced Glycation Endproducts (AGEs): A Review
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Transforming Cytosolic Proteins into “Insoluble” and Membrane-toxic Forms Triggering Diseases/Aging by Genetic, Pathological or Environmental Factors
Protein & Peptide Letters Targeting Exocytosis: Ins and Outs of the Modulation of Quantal Dopamine Release
CNS & Neurological Disorders - Drug Targets Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology